Business Wire

Massive Bio, Inc. to Partner With Veterans Prostate Cancer Awareness and Self-Care Catalysts to Accelerate Clinical Trial Enrollment and Digital Health Solutions

NEW YORK--(BUSINESS WIRE)--Massive Bio today announced it has entered a partnership with Veterans Prostate Cancer Awareness (VPCa), and Self-Care Catalysts to increase clinical trial and real-world ...
Nasdaq

Bio-Techne And ZERO - The End Of Prostate Cancer Announce Partnership To Fund Education And Awareness Campaigns To Empower Men With Prostate Cancer

MINNEAPOLIS, June 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with ZERO – The End of ...
Star Tribune

Prostate cancer test leads Bio-Techne's expansion into diagnostics

Bio-Techne Corp. is expanding into the realm of diagnostics with its ExoDx Prostate cancer test and a development pipeline of comparable products — a new area of business for the company, best known ...
Yahoo Finance

U.S. Prostate Cancer Biomarkers Industry Review 2021-2025 and Forecast to 2033 Featuring Strategic Insights of Key Players - Exact Sciences, Myriad Genetics, Bio-Techne, ExoDx ...

Dublin, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The "U.S. Prostate Cancer Biomarkers Market Size, Share & Trends Analysis 2025-2033" has been added to ResearchAndMarkets.com's offering. The U.S. prostate ...
FierceBiotech

Massive Bio teams up with veterans nonprofit to increase prostate cancer research, trial enrollment

Cancer trial matchmaker Massive Bio is teaming up with two organizations to boost clinical studies and research participation for prostate cancer. Massive Bio, Veterans Prostate Cancer Awareness and ...
Investing.com France

Le traitement ADC d’Akari montre des résultats prometteurs contre le cancer de la prostate résistant

BOSTON/LONDRES - Akari Therapeutics, Plc (NASDAQ:AKTX), une société de biotechnologie à petite capitalisation de 24,8 millions $, a annoncé mercredi que sa nouvelle charge utile d’anticorps conjugué ( ...
WDAF-TV

Deep Bio & Techcyte Partner to Integrate AI-Powered Prostate Diagnostics & Frozen Section on Techcyte Fusion® Platform

OREM, UT, UNITED STATES, August 26, 2025 /EINPresswire.com/ -- Deep Bio, a global leader in AI-powered cancer diagnostics, today announced a strategic partnership ...
Nasdaq

Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate Cancer

WORCESTER, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in ...
Yahoo Finance

INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial ...
MedCity News

Point Bio Prostate Cancer Therapy Meets Phase 3 Goal, But Results Still Disappoint

A Point Biopharma Global cancer therapy key to a $1.4 billion Eli Lilly M&A deal has met the main goal of its pivotal clinical trial in prostate cancer. But the results raise questions about how well ...
Business Insider

Bio-Techne's Exosome Diagnostics Laboratory Announces CE-IVD Certification For ExoDx Prostate Test

MINNEAPOLIS, March 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro ...